SVB Leerink analysts expect Abbott to gain share on Boston Scientific’s Watchman

Analysts believe Abbott (NYSE:ABT) may gain traction on Boston Scientific’s (NYSE:BSX) Watchman in the left atrial appendage closure (LAAC) space.

The second LAAC survey commissioned by SVB Leerink, which compared information from electrophysiologists to information from interventional cardiologists in the previous survey, pointed to the deceleration of Watchman volume expectations from double-digit growth in 2021-2022 down to high-single-digit-growth in 2023, according to analysis.

Analysts say that, although Abbott’s gain of traction in the LAAC space — with the company garnering FDA approval for its Amplatzer Amulet device earlier this month — comes to a lesser extent than Boston Scientific’s, the survey points to faster volume growth at centers adopting both devices and better Boston Scientific market share retention overall.

The surveyed electrophysiologists projected Abbott’s share shift at 18% in 2023 (against 24% share pro…

Read more
  • 0

Stryker sees pandemic sales effects softening

Stryker (NYSE:SYK) executives see hip and knee procedures growing in 2021, based on a trend that started in March and continued in April.

Such elective procedures were still sluggish in early 2021 due to the pandemic, but regional recovery from COVID-19 — particularly in the U.S. and Asia — bodes well for the company, CEO Kevin Lobo told analysts on the company’s first-quarter 2021 earnings call.

Stryker posted strong international sales of medical/surgical and sports medicine equipment compared with 2019, which Stryker execs chose for comparison purposes rather than 2020. The company also had double-digit organic growth (12.8%) in its interventional spine and neurotech businesses.

Sales of Stryker’s Mako robotic systems had a “banner” first quarter, Lobo said on the call, transcribed by Seeking Alpha, following similar positive results in Q4 2020. Mako sales lifted “other ortho” U.S. sales by 49% in the U.S. Stryker h…

Read more
  • 0

DTW Podcast: Zimmer Biomet slims, Corza Medical grows in pursuit of grabbing market share

In this week’s DeviceTalks Weekly Podcast, Rich Newitter, managing director at SVB Leerink, says Zimmer Biomet’s decision to spin out its spinal and dental business will accelerate its already impressive market share grab in its core orthopedics industry.

Dewitter says CEO Bryan Hanson brings a tried-and-true diversification model used by companies like his former employer, Covidien. The spinout of the spinal and dental businesses into a NewCo will allows the company to focus more resources on selling knee and hip implants as well as building out an impressive robotics franchise and a potentially sector-leading line of digital tools and sensors.

“Zimmer has effectively gone from a share loser for almost a decade leading up to when Bryan Hanson took over to a share-taking position,” he said in an interview with Chris Newmarker, executive editor of life sciences. “This most recent quarter, their share gains have widened quite dramatically.”

In …

Read more
  • 0